NovoCure (NVCR) Retained Earnings (2014 - 2026)

NovoCure (NVCR) has reported Retained Earnings for 13 consecutive years, with $1.7 billion the latest figure, recorded in Q2 2026.

• Quarterly Retained Earnings rose 8.56% year-over-year to $1.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 8.56% YoY) and the FY2025 annual result came in at $1.6 billion, up 7.53% from the prior year.
• Retained Earnings advanced to $1.7 billion in Q2 2026 per NVCR's latest filing, from $1.7 billion in the prior quarter.
• Over the last five years, Retained Earnings for NVCR reached as high as $1.7 billion in Q2 2026 and fell as low as $1.1 billion in Q1 2022.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings increased 12.8% — and 2025, when it increased 7.53%.
• Year by year, Retained Earnings stood at $1.2 billion in 2022, then climbed by 10.75% to $1.4 billion in 2023, then grew by 12.29% to $1.5 billion in 2024, then climbed by 7.53% to $1.6 billion in 2025, then rose by 5.16% to $1.7 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $1.7 billion, $1.7 billion, and $1.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.